Themedicines (the MHRA for Medicines and Healthcare Products Regulatory Agency) announced last Monday to approve an updated version of the against the made by . The booster vaccine called “bivalent” half targets the original strain of the of 2020 and half of the variant . indicates that it causes ” a strong immune response “, as well as'” a good against Omicron BA.4 and BA.5 sub-variants ».
« What this bivalent vaccine gives us is a sharper tool in our toolbox to help protect us against this disease as the virus continues to evolve. said Dr June Raine, Chief Executive of the MHRA. The agency says no serious safety issues were noted and the side effects observed were similar to those seen for the original Moderna booster dose.
The United Kingdom thus becomes the first country in the world to approve a bivalent vaccine that targetsvariant now most common in Europe.